EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY 4.0

Editorial: Myelodysplastic neoplasm and acute myeloid leukemia: multi-omics approaches and precision medicine

Teresa De Souza Fernandez, Chung Hoow Kok

Frontiers in Oncology · 15.05.2026 · 16

DOI: 10.3389/fonc.2026.1860744 ↗

Kurz gefasst

Editorial in der Zeitschrift Frontiers in Oncology, online erschienen am 15.05.2026. Verfasst von Teresa De Souza Fernandez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cytogenetic Laboratory, Cell and Gene Therapy Program, Instituto Nacional de Câncer, Rio de Janeiro, Brazil. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

clinical relevance of high-resolution genomic profiling, molecularly informed disease classification, immune and microenvironmental biology, artificial intelligence-assisted diagnosis, and emerging biomarkers with translational potential.A major theme across the collection is the increasing diagnostic value of integrated cytogenomic and molecular analysis in myeloid neoplasms. Cytogenetics plays an important role in myeloid neoplasms being incorporated in the risk prognostic scales, and for the genes identification involved in the leukemogenesis (1,2,(7)(8)(9). Tsai et al showed that the optical genome mapping (OGM) can complement conventional G-banding by improving the characterization of structural variants in leukemia. This study highlights the practical value of higher-resolution genomic technologies for resolving chromosomal complexity that may be incompletely defined by standard cytogenetics alone. Similarly, Mikkilineni et al reported two new myeloid neoplasm cases with MECOM::ETV6. Using a comprehensive approach including: histopathological, G-banding, FISH, NGS and it was also performed a review of literature for the structural abnormalities resulting in gene fusion between MECOM locus in hematologic neoplasms in public data bases. This study highlights the value of integrating histopathology, conventional cytogenetics, FISH, and NGS to define rare clinically relevant rearrangements. Chang et al further expanded the spectrum of recurrently detectable abnormalities by reporting a novel translocation t(5;17)(q24;q11.2) involving NF1::SCAMP5 identified by RNA-seq and confirmed by Sanger sequencing. In another case-based contribution, Wang and Jin showed for the first time a MDS/MPN patient harbouring SF3B1 mutation coexisting with the mutations in ASXL1, JAK2 and CBL. This case highlights the importance of integrative molecularmorphological framework that allowed a precision diagnosis evaluation.Beyond diagnosis, the collection also addresses mechanisms of disease evolution.Anemia (AA), MDS, and AML. These three diseases have complex pathogenic mechanisms and share clinical and molecular features. Identifying the factors that associated with disease progression is essential for preventing disease evolution to an advanced stage, and therefore critical for reducing treatment challenges (high relapse rates, drug resistance) and for improvement of therapeutic outcomes. The authors showed that POLG and MAP2K7 play a significant role throughout the progression from AA to MDS and to AML through the modulation of immune regulatory pathways, influencing disease transformation and progression. It is important to note that patients who have AML secondary from MDS have in general an unfavorable clinical evolution (10,11). This critical clinical outcome is also observed in patients with TP53 mutated in MDS and AML, that remains a major clinical challenge and is often associated with adverse outcomes (12,13). Complementing this theme, Albakri conducted a review that explored the mechanisms of immune dysfunction in TP53-mutated MDS and AML, focusing on the interplay between genetic lesions, tumor microenvironment, metabolism, and emerging therapeutic strategies. This review underscores the need for combinatorial approaches that integrate targeted, immunomodulatory, and metabolism-directed therapy as a transformative approach to improve patient outcomes in this biologically high-risk disease. This collection also highlights how precision medicine is being extended beyond sequencing-based approaches. In acute promyelocytic leukemia (APL), rapid diagnosis is essential because identification of PML::RARA has immediate therapeutic implications, particularly for the use of all-trans retinoic acid (ATRA) (14).Yan et al showed the importance of accurately diagnosing APL which accounts for 10-15% of all AML cases by developing an innovative artificial intelligence-based image analysis approach capable of identifying APL-associated fusion patterns directly from pathological images. Both classical APL and its variants differ in their biological characteristics and their response to ATRA. This study highlights how computational pathology may augment molecular Overall, this Research Topic collection demonstrates how the field is moving from single-platform testing toward integrated, multi-omics models in myeloid neoplasms.Collectively, the studies in this collection reinforce the concept that precision medicine in MDS and AML depends not only on the identification of genetic variants, but also on the interpretation of structural variation, transcriptional consequences, immune context, clinicopathologic phenotype, and, increasingly, image-derived computational data.

Schlagwörter

Stichwörter der Autor:innen

acute myeloid leukemiadiagnosismulti-omicsmyelodysplastic neoplasmsprecision medicineprognosis

Autor:innen und Institutionen

  • Cytogenetic Laboratory, Cell and Gene Therapy Program, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
  • Centre for Cancer Biology, College of Health, School of Medicine, Adelaide University, Adelaide, SA, Australia.
  • Data and Bioinformatics Innovation, Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.

Zitieren

APA

De Souza Fernandez, T., & Kok, C. H. (2026). Editorial: Myelodysplastic neoplasm and acute myeloid leukemia: multi-omics approaches and precision medicine. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1860744

Vancouver

De Souza Fernandez T, Kok CH. Editorial: Myelodysplastic neoplasm and acute myeloid leukemia: multi-omics approaches and precision medicine. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1860744

BibTeX
@article{DeSouzaFernandez2026,
  author = {De Souza Fernandez, Teresa and Kok, Chung Hoow},
  title = {Editorial: Myelodysplastic neoplasm and acute myeloid leukemia: multi-omics approaches and precision medicine},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1860744}
}
Kostenlos starten →